Brain and Mind Centre

Sydney, New South Wales 2050

0 studies enrolling now · 1 studies all time

What they study most

Multiple Sclerosis, Relapsing-Remitting

Studies at this site

• A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration — Completed